Clozapine for psychosis in Parkinson's disease
Identifieur interne : 003701 ( Istex/Corpus ); précédent : 003700; suivant : 003702Clozapine for psychosis in Parkinson's disease
Auteurs : Pfeiffer ; Jasbir Kang ; Benjamin Graber ; Ruth Hofman ; James WilsonSource :
- Movement Disorders [ 0885-3185 ] ; 1990.
English descriptors
- KwdEn :
Abstract
The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa‐induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5–25 mg daily, because of extreme sedation. Three patients could tolerate clozapine and experienced improvement or elimination of their hallucinations at doses below 100 mg daily. Despite a significant risk of adverse effects, cautious use of clozapine in low doses may be beneficial for patients with levodopa‐induced psychosis who do not respond to more conservative measures.
Url:
DOI: 10.1002/mds.870050310
Links to Exploration step
ISTEX:65DE8BD5CD8684100039B6B279090B594A6D36ADLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clozapine for psychosis in Parkinson's disease</title><author><name sortKey="Pfeiffer" sort="Pfeiffer" uniqKey="Pfeiffer" last="Pfeiffer">Pfeiffer</name><affiliation><mods:affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Kang, Jasbir" sort="Kang, Jasbir" uniqKey="Kang J" first="Jasbir" last="Kang">Jasbir Kang</name><affiliation><mods:affiliation>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Graber, Benjamin" sort="Graber, Benjamin" uniqKey="Graber B" first="Benjamin" last="Graber">Benjamin Graber</name><affiliation><mods:affiliation>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Hofman, Ruth" sort="Hofman, Ruth" uniqKey="Hofman R" first="Ruth" last="Hofman">Ruth Hofman</name><affiliation><mods:affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Wilson, James" sort="Wilson, James" uniqKey="Wilson J" first="James" last="Wilson">James Wilson</name><affiliation><mods:affiliation>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:65DE8BD5CD8684100039B6B279090B594A6D36AD</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1002/mds.870050310</idno><idno type="url">https://api.istex.fr/document/65DE8BD5CD8684100039B6B279090B594A6D36AD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003701</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clozapine for psychosis in Parkinson's disease</title><author><name sortKey="Pfeiffer" sort="Pfeiffer" uniqKey="Pfeiffer" last="Pfeiffer">Pfeiffer</name><affiliation><mods:affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Kang, Jasbir" sort="Kang, Jasbir" uniqKey="Kang J" first="Jasbir" last="Kang">Jasbir Kang</name><affiliation><mods:affiliation>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Graber, Benjamin" sort="Graber, Benjamin" uniqKey="Graber B" first="Benjamin" last="Graber">Benjamin Graber</name><affiliation><mods:affiliation>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Hofman, Ruth" sort="Hofman, Ruth" uniqKey="Hofman R" first="Ruth" last="Hofman">Ruth Hofman</name><affiliation><mods:affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Wilson, James" sort="Wilson, James" uniqKey="Wilson J" first="James" last="Wilson">James Wilson</name><affiliation><mods:affiliation>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1990">1990</date><biblScope unit="vol">5</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="239">239</biblScope><biblScope unit="page" to="242">242</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">65DE8BD5CD8684100039B6B279090B594A6D36AD</idno><idno type="DOI">10.1002/mds.870050310</idno><idno type="ArticleID">MDS870050310</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clozapine</term><term>Parkinson's disease</term><term>Psychosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa‐induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5–25 mg daily, because of extreme sedation. Three patients could tolerate clozapine and experienced improvement or elimination of their hallucinations at doses below 100 mg daily. Despite a significant risk of adverse effects, cautious use of clozapine in low doses may be beneficial for patients with levodopa‐induced psychosis who do not respond to more conservative measures.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dr. Pfeiffer</name><affiliations><json:string>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</json:string></affiliations></json:item><json:item><name>Jasbir Kang</name><affiliations><json:string>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</json:string></affiliations></json:item><json:item><name>Benjamin Graber</name><affiliations><json:string>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</json:string></affiliations></json:item><json:item><name>Ruth Hofman</name><affiliations><json:string>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</json:string></affiliations></json:item><json:item><name>James Wilson</name><affiliations><json:string>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Clozapine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Psychosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item></subject><language><json:string>eng</json:string></language><abstract>The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa‐induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5–25 mg daily, because of extreme sedation. Three patients could tolerate clozapine and experienced improvement or elimination of their hallucinations at doses below 100 mg daily. Despite a significant risk of adverse effects, cautious use of clozapine in low doses may be beneficial for patients with levodopa‐induced psychosis who do not respond to more conservative measures.</abstract><qualityIndicators><score>2.861</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 828 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>643</abstractCharCount><pdfWordCount>1757</pdfWordCount><pdfCharCount>11211</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>92</abstractWordCount></qualityIndicators><title>Clozapine for psychosis in Parkinson's disease</title><genre><json:string>Serial article</json:string></genre><host><volume>5</volume><pages><total>4</total><last>242</last><first>239</first></pages><issn><json:string>0885-3185</json:string></issn><issue>3</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1990</publicationDate><copyrightDate>1990</copyrightDate><doi><json:string>10.1002/mds.870050310</json:string></doi><id>65DE8BD5CD8684100039B6B279090B594A6D36AD</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/65DE8BD5CD8684100039B6B279090B594A6D36AD/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/65DE8BD5CD8684100039B6B279090B594A6D36AD/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/65DE8BD5CD8684100039B6B279090B594A6D36AD/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Clozapine for psychosis in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1990</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Clozapine for psychosis in Parkinson's disease</title><author><persName><surname>Pfeiffer</surname><roleName type="degree">Dr.</roleName></persName><note type="correspondence"><p>Correspondence: Section of Neurology, University of Nebraska Medical Center, 600 South 42nd St, Omaha, NE 68198‐2045, U.S.A.</p></note><affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation></author><author><persName><forename type="first">Jasbir</forename><surname>Kang</surname></persName><affiliation>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation></author><author><persName><forename type="first">Benjamin</forename><surname>Graber</surname></persName><affiliation>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation></author><author><persName><forename type="first">Ruth</forename><surname>Hofman</surname></persName><affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation></author><author><persName><forename type="first">James</forename><surname>Wilson</surname></persName><affiliation>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1990"></date><biblScope unit="vol">5</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="239">239</biblScope><biblScope unit="page" to="242">242</biblScope></imprint></monogr><idno type="istex">65DE8BD5CD8684100039B6B279090B594A6D36AD</idno><idno type="DOI">10.1002/mds.870050310</idno><idno type="ArticleID">MDS870050310</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1990</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa‐induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5–25 mg daily, because of extreme sedation. Three patients could tolerate clozapine and experienced improvement or elimination of their hallucinations at doses below 100 mg daily. Despite a significant risk of adverse effects, cautious use of clozapine in low doses may be beneficial for patients with levodopa‐induced psychosis who do not respond to more conservative measures.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Clozapine</term></item><item><term>Psychosis</term></item><item><term>Parkinson's disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1990">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/65DE8BD5CD8684100039B6B279090B594A6D36AD/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/mds.v5:3</doi><numberingGroup><numbering type="journalVolume" number="5">5</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="1990">1990</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="10" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870050310</doi><idGroup><id type="unit" value="MDS870050310"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1990 Movement Disorder Society</copyright><eventGroup><event type="firstOnline" date="2004-10-12"></event><event type="publishedOnlineFinalForm" date="2004-10-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">239</numbering><numbering type="pageLast">242</numbering></numberingGroup><correspondenceTo>Section of Neurology, University of Nebraska Medical Center, 600 South 42nd St, Omaha, NE 68198‐2045, U.S.A.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870050310.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="13"></count></countGroup><titleGroup><title type="main" xml:lang="en">Clozapine for psychosis in Parkinson's disease</title><title type="short" xml:lang="en">CLOZAPINE, PSYCHOSIS, AND PARKINSON'S DISEASE</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>Ronald F.</givenNames><familyName>Pfeiffer</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Jasbir</givenNames><familyName>Kang</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Benjamin</givenNames><familyName>Graber</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Ruth</givenNames><familyName>Hofman</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2"><personName><givenNames>James</givenNames><familyName>Wilson</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Clozapine</keyword><keyword xml:id="kwd2">Psychosis</keyword><keyword xml:id="kwd3">Parkinson's disease</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa‐induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5–25 mg daily, because of extreme sedation. Three patients could tolerate clozapine and experienced improvement or elimination of their hallucinations at doses below 100 mg daily. Despite a significant risk of adverse effects, cautious use of clozapine in low doses may be beneficial for patients with levodopa‐induced psychosis who do not respond to more conservative measures.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Clozapine for psychosis in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>CLOZAPINE, PSYCHOSIS, AND PARKINSON'S DISEASE</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Clozapine for psychosis in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">Pfeiffer</namePart><affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation><description>Correspondence: Section of Neurology, University of Nebraska Medical Center, 600 South 42nd St, Omaha, NE 68198‐2045, U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jasbir</namePart><namePart type="family">Kang</namePart><affiliation>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Benjamin</namePart><namePart type="family">Graber</namePart><affiliation>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ruth</namePart><namePart type="family">Hofman</namePart><affiliation>Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">James</namePart><namePart type="family">Wilson</namePart><affiliation>Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1990</dateIssued><copyrightDate encoding="w3cdtf">1990</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="references">13</extent></physicalDescription><abstract lang="en">The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa‐induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5–25 mg daily, because of extreme sedation. Three patients could tolerate clozapine and experienced improvement or elimination of their hallucinations at doses below 100 mg daily. Despite a significant risk of adverse effects, cautious use of clozapine in low doses may be beneficial for patients with levodopa‐induced psychosis who do not respond to more conservative measures.</abstract><subject lang="en"><genre>Keywords</genre><topic>Clozapine</topic><topic>Psychosis</topic><topic>Parkinson's disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>239</start><end>242</end><total>4</total></extent></part></relatedItem><identifier type="istex">65DE8BD5CD8684100039B6B279090B594A6D36AD</identifier><identifier type="DOI">10.1002/mds.870050310</identifier><identifier type="ArticleID">MDS870050310</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1990 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003701 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003701 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:65DE8BD5CD8684100039B6B279090B594A6D36AD
|texte= Clozapine for psychosis in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |